February 18, 2022

VISION trial: Radioligand therapy with 177Lu–PSMA-617 for mCRPC

Study shows prolonged imaging-based progression-free survival and overall survival when the radioligand therapy is added to standard care Prostate-specific membrane antigen (PSMA) is a transmembrane glutamate […]
October 22, 2020

SPARTAN: quality of life related to the use of apalutamide in patients with castration-resistant non-metastatic prostate cancer

There were no therapeutic options specifically approved for the population of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), but the evolution of therapeutic options has been […]